The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus.
Veerle van HultenJohanna H M DriessenJakob K Starup-LindeZheer K Al-MashhadiRikke ViggersOlaf H KlungelPatrick C SouvereinPeter VestergaardCoen D A StehouwerJoop P van den BerghPublished in: Diabetes, obesity & metabolism (2023)
Use of SGLT2 inhibitors was not associated with the risk of any fracture, MOFs or fracture at the individual MOF sites when compared to DPP-4 inhibitor use.
Keyphrases